TEVA PHARMACEUTICAL INDUSTRIES LIMITED Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period

TEVA PHARMACEUTICAL INDUSTRIES LIMITED (TEVA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period of 2.72 million shares for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-03.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod · last filed 2026-02-03

TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2025 was 2.72M shares, a 9.10% increase from fiscal 2024.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2024 was 2.50M shares, a 369.87% increase from fiscal 2023.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2023 was 531.00K shares, a 78.91% decline from fiscal 2022.
TEVA PHARMACEUTICAL INDUSTRIES LIMITED share-based compensation arrangement by share-based payment award, options, expirations in period for fiscal 2022 was 2.52M shares, a 2.21% decline from fiscal 2021.

Period end	Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period 12 month
2025-12-31	2.72M shares 10-K · filed 2026-02-03
2024-12-31	2.50M shares 10-K · filed 2026-02-03
2023-12-31	531.00K shares 10-K · filed 2026-02-03
2022-12-31	2.52M shares 10-K · filed 2025-02-05
2021-12-31	2.58M shares 10-K · filed 2024-02-12
2020-12-31	1.22M shares 10-K · filed 2023-02-10
2018-12-31	5.00K shares 10-K · filed 2021-02-10
2017-12-31	175.00K shares 10-K · filed 2020-02-21
2016-12-31	1.19M shares 10-K · filed 2019-02-19